Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre J Issa

Showing results (21-30 of 203) with videos related to

Pageof 21
Sort By:
Seminars in Hematology|July 15, 2005
Introduction: emerging role of epigenetic therapy: focus on decitabineJean-Pierre J Issa, Hagop M Kantarjian
Cancer Biology & Therapy|July 25, 2003
Mitoxantrone: a hypomethylating agent?Allen S Yang, Jean-Pierre J Issa
Genome Medicine|November 26, 2009
Tackling the methylome: recent methodological advances in genome-wide methylation profilingMarcos Rh Estécio, Jean-Pierre J Issa
Seminars in Hematology|July 15, 2005
Decitabine in chronic leukemiasJean-Pierre J Issa, John C Byrd
Cancer Prevention Research (Philadelphia, Pa.)|January 6, 2011
Time to think outside the (genetic) boxJean-Pierre J Issa, Judy E Garber
Current Opinion in Genetics & Development|April 17, 2017
The promise of epigenetic therapy: reprogramming the cancer epigenomeAndrew D Kelly, Jean-Pierre J Issa
Seminars in Hematology|July 15, 2005
Decitabine dosing schedulesHagop M Kantarjian, Jean-Pierre J Issa
FEBS Letters|December 15, 2010
Dissecting DNA hypermethylation in cancerMarcos R H Estécio, Jean-Pierre J Issa
Gastroenterology|September 7, 2005
CIMP, at lastJean-Pierre J Issa, Lanlan Shen, Minoru Toyota
Cold Spring Harbor Perspectives in Medicine|February 5, 2017
DNA Hypomethylating Drugs in Cancer TherapyTakahiro Sato, Jean-Pierre J Issa, Patricia Kropf
Pageof 21

Showing results (21-30 of 203) with videos related to

Sort By:
Pageof 21
Seminars in Hematology|July 15, 2005
Introduction: emerging role of epigenetic therapy: focus on decitabineJean-Pierre J Issa, Hagop M Kantarjian
Cancer Biology & Therapy|July 25, 2003
Mitoxantrone: a hypomethylating agent?Allen S Yang, Jean-Pierre J Issa
Genome Medicine|November 26, 2009
Tackling the methylome: recent methodological advances in genome-wide methylation profilingMarcos Rh Estécio, Jean-Pierre J Issa
Seminars in Hematology|July 15, 2005
Decitabine in chronic leukemiasJean-Pierre J Issa, John C Byrd
Cancer Prevention Research (Philadelphia, Pa.)|January 6, 2011
Time to think outside the (genetic) boxJean-Pierre J Issa, Judy E Garber
Current Opinion in Genetics & Development|April 17, 2017
The promise of epigenetic therapy: reprogramming the cancer epigenomeAndrew D Kelly, Jean-Pierre J Issa
Seminars in Hematology|July 15, 2005
Decitabine dosing schedulesHagop M Kantarjian, Jean-Pierre J Issa
FEBS Letters|December 15, 2010
Dissecting DNA hypermethylation in cancerMarcos R H Estécio, Jean-Pierre J Issa
Gastroenterology|September 7, 2005
CIMP, at lastJean-Pierre J Issa, Lanlan Shen, Minoru Toyota
Cold Spring Harbor Perspectives in Medicine|February 5, 2017
DNA Hypomethylating Drugs in Cancer TherapyTakahiro Sato, Jean-Pierre J Issa, Patricia Kropf
Pageof 21